Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)

ConclusionsIn patients with atrial fibrillation and/or mechanical heart valves who had warfarin interrupted for a procedure there was no benefit from post-procedure LMWH bridging.DisclosuresKovacs: Bayer: Research Funding; Daiichi Sankyo Pharma Development: Research Funding. Wells: Janssen: Honoraria; Sanofi: Honoraria; BMS: Honoraria, Research Funding; Bayer: Honoraria. Schulman: Boehringer-Ingelheim: Honoraria, Research Funding; Daiichi-Sankyo: Honoraria; Sanofi: Honoraria; Bayer: Honoraria.

Source: Blood - November 21, 2018 Category: Hematology Authors: Kovacs, M. J., Rodger, M., Wells, P. S., Bates, S. M., Kearon, C., Blostein, M., Lazo-Langner, A., Kahn, S., Schulman, S., Sabri, E., Solymoss, S., Ramsay, T., Pallaveshi, L., Anderson, D. Tags: 332. Antithrombotic Therapy: Management of Challenging Patients and Scenarios Source Type: research